Avo vs Zio

Avo's press release lists DynaMed (EBSCO Clinical Decisions), MCG and KDIGO as partners, and its buyer is a health system's informatics office rolling out guideline pathways. iRhythm sells a monitoring service. A wear-and-send Zio patch feeds a deep-learning arrhythmia analysis, cardiac technicians validate the findings, and a physician report follows. The company is public with 18 FDA 510(k) clearances, the latest the ZEUS Platform in May 2026, and the vendor lists CE, UKCA and PMDA marks. It bills through Medicare-enrolled IDTFs and publishes no price. The record includes an FDA warning letter of May 25, 2023 over Zio AT changes, with a Form 483 after July 2024 inspections, and the 10-K says FDA issues remain open and a further warning letter, consent decree or recall is possible.

A cardiology group that wants ambulatory ECG monitoring cannot get it from Avo, and an informatics office that wants pathways in the chart cannot get them from a patch.